Functional proteomics of breast cancer for signal pathway profiling and target discovery

Journal of Mammary Gland Biology and Neoplasia

Volumn 7, Issue 4, 2002, Pages 395-405

  Hondermarck, Hubert ^a   Dollé, Laurent ^a   Yazidi Belkoura, Ikram El ^a   Vercoutter Edouart, Anne Sophie ^b   Adriaenssens, Eric ^a   Lemoine, Jérôme ^b  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

Author keywords

Breast cancer; Growth signaling pathways; Proteomics; Therapeutic targets

Indexed keywords

CHAPERONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL RECEPTOR; FIBROBLAST GROWTH FACTOR 2; FOCAL ADHESION KINASE; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIN RECEPTOR; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN 14 3 3; PROTEIN 14 3 3 SIGMA; PROTEIN P53; PROTEIN TYROSINE KINASE; RAC1 PROTEIN; SCATTER FACTOR; SOMATOMEDIN C; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; GROWTH PROMOTOR; MESSENGER RNA; PROTEOME;

APOPTOSIS; BIOINFORMATICS; BREAST CANCER; BREAST CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; MASS SPECTROMETRY; METASTASIS; PARACRINE SIGNALING; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; BREAST TUMOR; METABOLISM; PROGNOSIS;

BREAST NEOPLASMS; GROWTH SUBSTANCES; HUMANS; MODELS, BIOLOGICAL; PROGNOSIS; PROTEOME; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 0141447431     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024086015542     Document Type: Review

References (60)

1. K. L. Cheung, C. R. Graves, and J. F. Robertson (2000). Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat. Rev. 26:91-102.
2. D. R. Ciocca and R. Elledge (2000). Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13:1-10.
3. D. Haber (2000). Roads leading to breast cancer. N. Engl. J. Med. 343:1566-1568.
4. C. K. Osborne (1998). Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339:1609-1618.
5. S. P. Ethier (1995). Growth factor synthesis and human breast cancer progression. J. Natl. Cancer Inst. 87:964-973.
6. X. F. LeBourhis, R. A. Toillon, B. Boilly, and H. Hondermarck (2000). Autocrine and paracrine growth inhibitors of breast cancer cells. Breast Cancer Res. Treat. 60:251-258.
7. N. Rahimi, W. Hung, E. Tremblay, R. Saulnier, and B. Elliott (1998). c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem. 273:33714-33721.
8. D. M. Ornitz and N. Itoh (2001). Fibroblast growth factors. Genome Biol. 2:3005.1-3005.12.
9. V. D. Blanckaert, M. Hebbar, M. M. Louchez, M. O. Vilain, M. E. Schelling, and J. P. Peyrat (1998). Basic Fibroblast growth factor and their prognostic value in human breast cancer. Clin. Cancer Res. 4:2939-2947.
10. V. Nurcombe, C. E. Smart, H. Chipperfield, S. M. Cool, B. Boilly, and H. Hondermarck (2000). The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J. Biol. Chem. 275:30009-30018.
11. H. Rahmoune, H. L. Chen, J. T. Gallagher, P. S. Rudland, and D. G. Fernig (1998). Interaction of heparan sulfate from mammary gland cells with acid fibroblast growth factor and basic FGF. Regulation of the activity of bFGF by high and low affinity binding sites in heparan sulfate. J. Biol. Chem. 273:7303-7310.
12. B. Boilly, A. S. Vercoutter-Edouart, H. Hondermarck. V. Nurcombe, and X. Le Bourhis (2000). Fibroblast growth factor signals for cell proliferation and migration through different pathways. Cytokine Growth Factor Rev. 11:295-302.
13. S. Descamps, X. Lebourhis, M. Delehedde, B. Boilly, and H. Hondermarck (1998). Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J. Biol. Chem. 273:16659-16662.
14. S. Descamps, R. A. Toillon, E. Adriaenssens, V. Pawlowski, S. M. Cool, V. Nurcombe, X. Le Bourhis, B. Boilly, J. P. Peyrat, and H. Hondermarck (2001). Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J. Biol. Chem. 276:17864-17870.
15. E. Tagliabue, F. Castiglioni, C. Ghirelli, M. Modugno, L. Asnaghi, C. Melani, and S. Menard (2000). Nerve growth factor cooperates with p185HER-2 in activating growth of human breast carcinoma cells. J. Biol. Chem. 275:5388-5394.
16. A. Chiarenza, P. Lazarovici, L. Lempereur, G. Cantarelle, A. Bianchi, and R. Bernardini (2001). Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line. Cancer Res. 61:3002-3008.
17. J. Bonneterre, J. P. Peyrat, R. Beuscart, and A. Demaille (1990). Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res. 50:6931-6935.
18. V. D. Blanckaert, M. Hebbar, M. M. Louchez, M. O. Vilain, M. E. Schelling, and J. P. Peyrat (1998). Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin. Cancer Res. 4:2939-2947.
19. V. Pawlowski, F. Revillion, M. Hebbar, L. Hornez, and J. P. Peyrat (2000). Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin. Cancer Res. 6:4217-4225.
20. S. Descamps, V. Pawlowski, F. Revillion, L. Hornez, M. Hebbar, B. Boilly, H. Hondermarck, and J. P. Peyrat (2001). Expression of nerve growth factor receptors and their pronostic value in human breast cancer. Cancer Res. 61:4337-4340.
21. S. J. Nass, H. A. Hahm, and N. E. Davidson (1998). Breast cancer biology blossoms in the clinic. Nat. Med. 4:761-762.
22. H. Hondermarck, C. S. McLaughlin, S. D. Patterson, and R. A. Bradshaw (1994). Early changes in protein synthesis induced by basic fibroblast growth factor, nerve growth factor, and epidermal growth factor in PC12 pheochromocytoma cells. Proc. Natl. Acad. Sci. U.S.A. 91:9377-9381.
23. V. Soskic, M. Gorlach, S. Poznanovic, F. D. Boehmer, and J. Godovac-Zimmermann (1999). Functional proteomics analysis of signal transduction pathways of the platelet-derived growth factor beta receptor. Biochemistry 38:1757-1764.
24. A. Pandey, A. V. Podtelejnikov, B. Blagoev, X. R. Bustelo, M. Mann, and H. F. Lodish (2000). Analysis of receptor signaling pathways by mass spectrometry: Identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 97:179-184.
25. J. F. Liu, E. Chevet, S. Kebache, G. Lemaitre, D. Barritault, L. Larose, and M. Crepin (1999). Functional Rac-1 and Nck signaling networks are required for FGF-2-induced DNA synthesis in MCF-7 cells. Oncogene 18:6425-6433.
26. A. S. Vercoutter-Edouart, J. Lemoine, C. E. Smart, V. Nurcombe, B. Boilly, J. P. Peyrat, and H. Hondermarck (2000). The mitogenic signaling pathway for fibroblast growth factor-2 involves the tyrosine phosphorylation of cyclin D2 in MCF-7 human breast cancer cells. FEBS Lett. 478:209-215.
27. A. S. Vercoutter-Edouart, X. Czeszak, M. Crepin, J. Lemoine, B. Boilly, X. Le Bourhis, J. P. Peyrat, and H. Hondermarck (2001). Proteomic detection of changes in protein synthesis induced by fibroblast growth factor-2 in MCF-7 human breast cancer cells. Exp. Cell Res. 262:59-68.
28. C. Jolly and R. I. Morimoto (2000). Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl. Cancer Inst. 92:1564-1572.
29. R. Colomer, L. A. Shamon, M. S. Tsai, and R. Lupu (2001). Herceptin: From the bench to the clinic. Cancer Invest. 19:49-56.
30. L. H. Pearl and C. Prodromou (2000). Structure and in vivo function of HSP90. Curr. Opin. Struct. Biol. 10:46-51.
31. H. Fu, R. R. Subramanian, and S. C. Masters (2000). 14-3-3 proteins: Structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 40:617-647.
32. A. S. Vercoutter-Edouart, J. Lemoine, X. Le Bourhis, H. Louis, B. Boilly, V. Nurcombe, F. Revillion, J. P. Peyrat, and H. Hondermarck (2001). Proteomic analysis reveals that 14-3-3 sigma is down-regulated in human breast cancer cells. Cancer Res. 61:76-80.
33. A. T. Ferguson, E. Evron, C. B. Umbricht, T. K. Pandita, T. A. Chan, H. Hermeking, J. R. Marks, A. R. Lambers, P. A. Futreal, M. R. Stampfer, and S. Sukumar (2000). High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 97:6049-6054.
34. S. Li and G. D. Shipley (1991). Expression of multiple species of basic fibroblast growth factor mRNA and protein in normal and tumor-derived mammary epithelial cells in culture. Cell Growth Differ. 2:195-202.
35. H. Hermeking, C. Lengauer, K. Polyak, T. C. He, L. Zhang, S. Thiagalingam, K. W. Kinzler, and B. Vogelstein (1997). 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1:3-11.
36. C. Laronga, H. Y. Yang, C. Neal, and M. H. Lee (2000). Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J. Biol. Chem. 275:23106-23112.
37. C. I. Brannan, E. C. Dees, R. S. Ingram, and S. M. Tilghman (1990). The product of the H19 gene may function as an RNA. Mol. Cell. Biol. 10:28-36.
38. Y. Hao, T. Crenshaw, T. Moulton, E. Newcomb, and B. Tycko (1993). Tumour-suppressor activity of H19 RNA. Nature 365:764-767.
39. E. Adriaenssens, S. Lottin, N. Berteaux, L. Hornez, W. Fauquette, V. Fafeur, J. P. Peyrat, X. Le Bourhis, H. Hondermarck, J. Coll, T. Dugimont, and J. J. Curgy (2002). Cross-talk between mesenchyme and epithelium increases H19 gene expression during scattering and morphogenesis of epithelial cells. Exp. Cell Res. 275:215-229.
40. S. Lottin, E. Adriaenssens, T. Dupressoir, N. Berteaux, C. Montpellier, J. Coll, T. Dugimont, and J. J. Curgy (2002). Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis, 23:1885-1895.
41. S. Lottin, A. S. Vercoutter-Edouart, E. Adriaenssens, X. Czeszak, J. Lemoine, M. Roudbaraki, J. Coll, H. Hondermarck, T. Dugimont, and J. J. Curgy (2002). Thioredoxin post-transcriptional regulation by H19 provides a new function to mRNA-like non-coding RNA. Oncogene 21:1625-1631.
42. H. Nakamura, K. Nakamura, and J. Yodoi (1997). Redox regulation of cellular activation. Annu. Rev. Immunol. 15:351-369.
43. K. Hirota, M. Murata, T. Itoh, J. Yodoi, and K. Fukuda (2001). Redox-sensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation. J. Biol. Chem. 276:25953-25958.
44. G. L. Wright, Jr. (1974). Two-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Annu. Clin. Lab. Sci. 4:281-293.
45. B. Westley and H. Rochefort (1980). A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20:353-362.
46. D. K. Trask, V. Band, D. A. Zajchowski, P. Yaswen, T. Suh, and R. Sager (1990). Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 87:2319-2323.
47. J. Stastny, R. Prasad, and E. Fosslien (1984). Tissue proteins in breast cancer, as studied by use of two-dimensional electrophoresis. Breast Cancer Res. Treat. 30:1914-1918.
48. P. J. Wirth, V. Egilsson, V. Gudnason, S. Ingvarsson, and S. S. Thorgeirsson (1987). Specific polypeptide differences in normal versus malignant human breast tissues by two-dimensional electrophoresis. Breast Cancer Res. Treat. 10:177-189.
49. P. J. Wirth (1989). Specific polypeptide differences in normal versus malignant breast tissue by two-dimensional electrophoresis. Electrophoresis 10:543-554.
50. P. J. Worland, D. Bronzert, R. B. Dickson, M. E. Lippman, L. Hampton, S. S. Thorgeirsson, and P. J. Wirth (1989). Secreted and cellular polypeptide patterns of MCF-7 human breast cancer cells following either estrogen stimulation or v-H-ras transfection. Cancer Res. 49:51-57.
51. T. M. Maloney, P. L. Paine, and J. Russo (1989). Polypeptide composition of normal and neoplastic human breast tissues and cells analyzed by two-dimensional gel electrophoresis. Breast Cancer Res. Treat. 14:337-348.
52. R. A. Craven and R. E. Banks (2001). Laser capture microdissection and proteomics: Possibilities and limitation. Proteomics 1:1200-1204.
53. S. P. Gygi, B. Rist, S. A. Gerber, F. Turecek, M. H. Gelb, and R. Aebersold (1999). Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17:994-999.
54. H. J. Issaq (2001). The role of separation science in proteomics research. Electrophoresis 22:3629-3638.
55. S. R. Weinberger, T. S. Morris, and M. Pawlak (2000). Recent trends in protein biochip technology. Pharmacogenomics 1:395-416.
56. K. K. Jain (2002). Post-genomic applications of lab-on-a-chip and microarrays. Trends Biotechnol. 20:184-185.
57. R. W. Nelson, D. Nedelkov, and K. A. Tubbs (2000). Biosensor chip mass spectrometry: A chip-based proteomics approach. Electrophoresis 21:1155-1163.
58. E. T. Fung, V. Thulasiraman, S. R. Weinberger, and E. A. Dalmasso (2001). Protein biochips for differential profiling. Curr. Opin. Biotechnol. 12:65-69.
59. J. E. Celis, M. Kruhoffer, I. Gromova, C. Frederiksen, M. Ostergaard, T. Thykjaer, P. Gromov, J. Yu, H. Palsdottir, N. Magnusson, and T. F. Orntoft (2000). Gene expression profiling: Monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett. 480:2-16.
60. S. M. Hanash (2001). Global profiling of gene expression in cancer using genomics and proteomics. Curr. Opin. Mol. Ther. 3:538-545.